Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549) | Bian et al. Journal of Experimental Clinical Cancer Research 2011 30 20 http content 30 1 20 Journal of Experimental Clinical Cancer Research RESEARCH Open Access Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line A549 Hai-Bo Bian1 Xuan Pan1 Jin-Song Yang2 3 Zhao-Xia Wang1 Wei De3 Abstract Background Recently miR-451 as a tumor suppressor has been reported in other studies. However whether miR-451 can affect the sensitivity of non-small cell lung cancer NSCLC cells to cisplatin DDP remains unclear. The aim of this study is to evaluate the roles of miR-451 in the sensitivity of NSCLC cells to DDP. Methods Quantitative RT-PCR assay was performed to detect the expression of miR-451 in 10 pairs of NSCLC and noncancerous tissue samples. pcDNA-GW EmGFP-miR-451 was stably transfected into NSCLC cell line A549 . Then the effects of miR-451 upregulation on growth colony formation and apoptosis of A549 cells were investigated. Finally the effects of miR-451 upregulation on in vitro and in vivo sensitivity of A549 cells of DDP were also determined. Results The level of miR-451 expression in NSCLC tissues was significantly higher than that in corresponding noncancerous tissues. Ectopic overexpression of miR-451 could significantly inhibit growth and induce apoptosis of A549 cells. Moreover ectopic overexpression of miR-451 could sensitize A549 cells to DDP possibly by increasing DDP-induced apoptosis which might be associated with the inactivation of Akt signaling pathway. Conclusions This study demonstrated for the first time that combination of DDP application with miR-451 upregulation might be a potential strategy for the treatment of human NSCLC. Background NSCLC accounts for the majority of lung cancer cases and chemotherapy has been the mainstay of treatments of lung cancers 1 . Up to date DDP still remains the most widely used first-line chemotherapeutic agent for NSCLC treatment. However continuous .